Epigenetic profiling of cutaneous T-cell lymphoma: Promoter hypermethylation of multiple tumor suppressor genes including BCL7a, PTPRG, and p73

Journal of Clinical Oncology

Volumn 23, Issue 17, 2005, Pages 3886-3896

  Van Doorn, Remco ^a   Zoutman, Willem H ^a   Dijkman, Remco ^a   De Menezes, Renee X ^a   Commandeur, Suzan ^a   Mulder, Aat A ^a   Van Der Velden, Pieter A ^a   Vermeer, Maarten H ^a   Willemze, Rein ^a   Yan, Pearlly S ^a   Huang, Tim H ^a   Tensen, Cornelis P ^a  

^a LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

PROTEIN P15; PROTEIN P16; PROTEIN P73; THROMBOSPONDIN; ACTIN BINDING PROTEIN; BCL7A PROTEIN, HUMAN; CD30 ANTIGEN; DNA; DNA BINDING PROTEIN; NERVE PROTEIN; NUCLEAR PROTEIN; ONCOPROTEIN; PROTEIN TYROSINE PHOSPHATASE; RECEPTOR PROTEIN TYROSINE PHOSPHATASE GAMMA; THROMBOSPONDIN 4; TUMOR SUPPRESSOR PROTEIN; TUMOR SUPPRESSOR PROTEIN P73;

ADULT; AGED; ARTICLE; BCL7ALPHA GENE; CONTROLLED STUDY; CPG ISLAND; CUTANEOUS T CELL LYMPHOMA; DNA ISOLATION; DNA METHYLATION; EPIGENETICS; FEMALE; GENE MUTATION; GENE SEQUENCE; GENETIC SCREENING; GENOME ANALYSIS; HUMAN; HUMAN TISSUE; MALE; NUCLEOTIDE SEQUENCE; PATHOGENESIS; PRIORITY JOURNAL; PROMOTER REGION; PTPRG GENE; TMS1 GENE; TUMOR SUPPRESSOR GENE; COMPARATIVE STUDY; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION; GENE SILENCING; GENETIC EPIGENESIS; GENETICS; GENOME; METABOLISM; MICROARRAY ANALYSIS; MIDDLE AGED; MOLECULAR GENETICS; PHYSIOLOGY; SKIN TUMOR;

ADULT; AGED; AGED, 80 AND OVER; ANTIGENS, CD30; BASE SEQUENCE; CPG ISLANDS; DNA METHYLATION; DNA, NEOPLASM; DNA-BINDING PROTEINS; EPIGENESIS, GENETIC; FEMALE; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION, NEOPLASTIC; GENE SILENCING; GENES, TUMOR SUPPRESSOR; GENOME, HUMAN; HUMANS; LYMPHOMA, T-CELL, CUTANEOUS; MALE; MICROARRAY ANALYSIS; MICROFILAMENT PROTEINS; MIDDLE AGED; MOLECULAR SEQUENCE DATA; NERVE TISSUE PROTEINS; NUCLEAR PROTEINS; ONCOGENE PROTEINS; PROMOTER REGIONS (GENETICS); PROTEIN-TYROSINE-PHOSPHATASE; SKIN NEOPLASMS; THROMBOSPONDINS; TUMOR SUPPRESSOR PROTEINS;

EID: 21244458051     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.2005.11.353     Document Type: Article

References (56)

1. Willemze R, Kerl H, Sterry W, et al: EORTC classification for primary cutaneous lymphomas: A proposal from the Cutaneous Lymphoma Study Group of the European Organization for Research and Treatment of Cancer. Blood 90:354-371, 1997
2. van Doom R, Dijkman R, Vermeer MH, et al: A novel splice variant of the Fas gene in patients with cutaneous T-cell lymphoma. Cancer Res 62:5389-5392, 2002
3. Capocasale RJ, Lamb RJ, Vonderheid EC, et al: Reduced surface expression of transforming growth factor beta receptor type II in mitogen-activated T cells from Sezary patients. Proc Natl Acad Sci U S A 92:5501-5505, 1995
4. Sommer VH, Clemmensen OJ, Nielsen O, et al: In vivo activation of STAT3 in cutaneous T-cell lymphoma. Evidence for an antiapoptotic function of STAT3. Leukemia 18:1288-1295, 2004
5. Mao X, Lillington DM, Czepulkowski B, et al: Molecular cytogenetic characterization of Sezary syndrome. Genes Chromosomes Cancer 36:250-260, 2003
6. Navas IC, Ortiz-Romero PL, Villuendas R, et al: p16(INK4a) gene alterations are frequent in lesions of mycosis fungoides. Am J Pathol 156:1565-1572, 2000
7. Scarisbrick JJ, Woolford AJ, Calonje E, et al: Frequent abnormalities of the p15 and p16 genes in mycosis fungoides and Sezary syndrome. J Invest Dermatol 118:493-499, 2002
8. Zhang Q, Raghunath PN, Vonderheid E, et al: Lack of phosphotyrosine phosphatase SHP-1 expression in malignant T-cell lymphoma cells results from methylation of the SHP-1 promoter. Am J Pathol 157:1137-1146, 2000
9. Scarisbrick JJ, Mitchell TJ, Calonje E, et al: Microsatellite instability is associated with hypermethylation of the hMLH1 gene and reduced gene expression in mycosis fungoides. J Invest Dermatol 121:894-901, 2003
10. Deng G, Song GA, Pong E, et al: Promoter methylation inhibits APC gene expression by causing changes in chromatin conformation and interfering with the binding of transcription factor CCAAT-binding factor. Cancer Res 64: 2692-2698, 2004
11. Herman JG, Baylin SB: Gene silencing in cancer in association with promoter hypermethylation. N Engl J Med 349:2042-2054, 2003
12. Costello JF, Fruhwald MC, Smiraglia DJ, et al: Aberrant CpG-island methylation has non-random and tumour-type-specific patterns. Nat Genet 24:132-138, 2000
13. Esteller M, Corn PG, Baylin SB, et al: A gene hypermethylation profile of human cancer. Cancer Res 61:3225-3229, 2001
14. Laird PW: The power and the promise of DNA methylation markers. Nat Rev Cancer 3: 253-266, 2003
15. Egger G, Liang G, Aparicio A, et al: Epigenetics in human disease and prospects for epigenetic therapy. Nature 429:457-463, 2004
16. Piekarz RL, Robey R, Sandor V, et al: Inhibitor of histone deacetylation, depsipeptide (FR901228), in the treatment of peripheral and cutaneous T cell lymphoma: A case report. Blood 98:2865-2868, 2001
17. Esteller M: Profiling aberrant DNA methylation in hematologic neoplasms: A view from the tip of the iceberg. Clin Immunol 109:80-88, 2003
18. Kondo Y, Shen L, Yan PS, et al: Chromatin immunoprecipitation microarrays for identification of genes silenced by histone H3 lysine 9 methylation. Proc Natl Acad Sci U S A 101:7398-7403, 2004
19. Yan PS, Chen CM, Shi H, et al: Applications of CpG island microarrays for high-throughput analysis of DNA methylation. J Nutr 132:24305-24345, 2002 (suppl)
20. Yan PS, Efferth T, Chen HL, et al: Use of CpG island microarrays to identify colorectal tumors with a high degree of concurrent methylation. Methods 27:162-169, 2002
21. Vergier B, de Muret A, Beylot-Barry M, et al: Transformation of mycosis fungoides: clinicopathological and prognostic features of 45 cases. French Study Group of Cutaneious Lymphomas. Blood 95:2212-2218, 2000
22. Bekkenk MW, Geelen FA, van Voorst Vader PC, et al: Primary and secondary cutaneous CD30(+) lymphoproliferative disorders: A report from the Dutch Cutaneous Lymphoma Group on the long-term follow-up data of 219 patients and guidelines for diagnosis and treatment. Blood 95:3653-3661, 2000
23. Huber W, von Heydebreck A, Sultmann H, et al: Variance stabilization applied to microarray data calibration and to the quantification of differential expression. Bioinformatics 18:S96-104, 2002 (suppl)
24. Benjamini Y, Hochberg Y: Controlling the false discovery rate: A practical and powerful approach to multiple testing. J R Statist Soc B 57:289-300, 1995
25. Toyota M, Kopecky KJ, Toyota MO, et al: Methylation profiling in acute myeloid leukemia. Blood 97:2823-2829, 2001
26. Garcia-Manero G, Daniel J, Smith TL, et al: DNA methylation of multiple promoter-associated CpG islands in adult acute lymphocytic leukemia. Clin Cancer Res 8:2217-2224, 2002
27. Kaltoft K, Bisballe S, Dyrberg T, et al: Establishment of two continuous T-cell strains from a single plaque of a patient with mycosis fungoides. In Vitro Cell Dev Biol 28A:161-167, 1992 (3pt 1)
28. Yan PS, Chen CM, Shi H, et al: Dissecting complex epigenetic alterations in breast cancer using CpG island microarrays. Cancer Res 61: 8375-8380, 2001
29. Wei SH, Chen CM, Strathdee G, et al: Methylation microarray analysis of late-stage ovarian carcinomas distinguishes progression-free survival in patients and identifies candidate epigenetic markers. Clin Cancer Res 8:2246-2252, 2002
30. Zhu X, Deng C, Kuick R, et al: Analysis of human peripheral blood T cells and single-cell-derived T cell clones uncovers extensive clonal CpG island methylation heterogeneity throughout the genome. Proc Natl Acad Sci U S A 96:8058-8063, 1999
31. Rush LJ, Dai Z, Smiraglia DJ, et al: Novel methylation targets in de novo acute myeloid leukemia with prevalence of chromosome 11 loci. Blood 97:3226-3233, 2001
32. Sengupta PK, Smith EM, Kim K, et al: DNA hypermethylation near the transcription start site of collagen alpha2(I) gene occurs in both cancer cell lines and primary colorectal cancers. Cancer Res 63:1789-1797, 2003
33. Fraga MF, Esteller M: DNA methylation: A profile of methods and applications. Biotechniques 33:632,634,636-49, 2002
34. Kawano S, Miller CW, Gombart AF, et al: Loss of p73 gene expression in leukemias/ lymphomas due to hypermethylation. Blood 94:1113-1120, 1999
35. Esteller M, Gaidano G, Goodman SN, et al: Hypermethylation of the DNA repair gene O(6)-methylguanine DNA methyltransferase and survival of patients with diffuse large B-cell lymphoma. J Natl Cancer Inst 94:26-32, 2002
36. Chim CS, Wong KY, Loong F, et al: SOCS1 and SHP1 hypermethylation in mantle cell lymphoma and follicular lymphoma: Implications for epigenetic activation of the Jak/STAT pathway. Leukemia 18:356-358, 2004
37. Conway KE, McConnell BB, Bowring CE, et al: TMS1, a novel proapoptotic caspase recruitment domain protein, is a target of methylation-induced gene silencing in human breast cancers. Cancer Res 60:6236-6242, 2000
38. Toyota M, Sasaki Y, Satoh A, et al: Epigenetic inactivation of CHFR in human tumors. Proc Natl Acad Sci U S A 100:7818-7823, 2003
39. Roman-Gomez J, Jimenez-Velasco A, Castillejo JA, et al: Promoter hypermethylation of cancer-related genes: A strong independent prognostic factor in acute lymphoblastic leukemia. Blood 104:2492-2498, 2004
40. Zani VJ, Asou N, Jadayel D, et al: Molecular cloning of complex chromosomal translocation t(8;14;12)(q24.1;q32.3;q24.1) in a Burkitt lymphoma cell line defines a new gene (BCL7A) with homology to caldesmon. Blood 87:3124-3134, 1996
41. Tracey L, Villuendas R, Dotor AM, et al: Mycosis fungoides shows concurrent deregulation of multiple genes involved in the TNF signaling pathway: An expression profile study. Blood 102:1042-1050, 2003
42. Martinez-Delgado B, Melendez B, Cuadros M, et al: Expression profiling of T-cell lymphomas differentiates peripheral and lymphoblastic lymphomas and defines survival related genes. Clin Cancer Res 10:4971-4982, 2004
43. Alizadeh AA, Eisen MB, Davis RE, et al: Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling. Nature 403:503-511, 2000
44. Motiwala T, Ghoshal K, Das A, et al: Suppression of the protein tyrosine phosphatase receptor type O gene (PTPRO) by methylation in hepatocellular carcinomas. Oncogene 22:6319-6331, 2003
45. Wang Z, Shen D, Parsons DW, et al: Mutational analysis of the tyrosine phosphatome in colorectal cancers. Science 304:1164-1166, 2004
46. LaForgia S, Morse B, Levy J, et al: Receptor protein-tyrosine phosphatase gamma is a candidate tumor suppressor gene at human chromosome region 3p21. Proc Natl Acad Sci USA 88:5036-5040, 1991
47. Ahuja N, Mohan AL, Li Q, et al: Association between CpG island methylation and microsatellite instability in colorectal cancer. Cancer Res 57:3370-3374, 1997
48. Esteller M, Garcia-Foncillas J, Andion E, et al: Inactivation of the DNA-repair gene MGMT and the clinical response of gliomas to alkylating agents. N Engl J Med 343:1350-1354, 2000
49. Rossi D, Capello D, Gloghini A, et al: Aberrant promoter methylation of multiple genes throughout the clinico-pathologic spectrum of B-cell neoplasia. Haematologica 89:154-164, 2004
50. Reddy AN, Jiang WW, Kim M, et al: Death-associated protein kinase promoter hypermethylation in normal human lymphocytes. Cancer Res 63:7694-7698, 2003
51. Lissy NA, Davis PK, Irwin M, et al: A common E2F-1 and p73 pathway mediates cell death induced by TCR activation. Nature 407:642-645, 2000
52. Martinez-Delgado B, Melendez B, Cuadros M, et al: Frequent inactivation of the p73 gene by abnormal methylation or LOH in non-Hodgkin's lymphomas. Int J Cancer 102:15-19, 2002
53. Siu LL, Chan JK, Wong KF, et al: Aberrant promoter CpG methylation as a molecular marker for disease monitoring in natural killer cell lymphomas. Br J Haematol 122:70-77, 2003
54. Issa JP, Garcia-Manero G, Giles FJ, et al: Phase 1 study of low-dose prolonged exposure schedules of the hypomethylating agent 5-aza-2′- deoxycytidine (decitabine) in hematopoietic malignancies. Blood 103:1635-1640, 2004
55. Cheng JC, Yoo CB, Weisenberger DJ, et al: Preferential response of cancer cells to zebularine. Cancer Cell 6:151-158, 2004
56. Davis AJ, Gelmon KA, Siu LL, et al: Phase I and pharmacologic study of the human DNA methyltransferase antisense oligodeoxynucleotide MG98 given as a 21-day continuous infusion every 4 weeks. Invest New Drugs 21:85-97, 2003